Amgen, Inc. vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $416.5 (market cap $224.14B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.62. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | HYG | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $81.32 |
52-Week Low | $271.18 | $78.72 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.63 with minimal daily movement (+0.19%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights investor rotation into fixed income ETFs amid rising yields, though specific articles question HYG's competitiveness versus peers on expenses and performance.
The outlook for HYG is clouded by bearish technicals and mixed sentiment. Opportunities exist from high-yield demand, but risks include rising interest rates, inflation fears, and underperformance versus alternatives. Investors should weigh the ETF's 6.5% yield against potential downside from economic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →